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It was suggested that in contrast to the E4 allele, the E2 allele of the apolipoprotein E gene (APOE"2) has a protective 
effect for late-onset Alzheimer's disease and early-onset Alzheimer's disease (EOAD). We studied the role of the 
APOE*2 allele in the pathogenesis of EOAD in a Dutch population-based study of 175 probable EOAD patients with 
onset age at or before 65 years and 532 age-matched controls. In our population, there was no evidence for a protective 
effect of the APOE"2 allele on the risk of EOAD. However, our data show that among EOAD patients, survival for 
APOE"2 carriers was significantly reduced. When restricting the analysis to patients ascertained early after diagnosis 
at a stage of disease when mortality is low, our data suggest an increased risk of EOAD for subjects with APOE2E2, 
APOE2E3, APOE3E4, and APOE4E4 genotypes. 
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Apolipoprotein E (apoE) has three isoforms, apoE-~2, 
apoE-~3, and apoE-~4. The biosynthesis of these iso- 
forms is fully determined by the apoE gene (APOE) 
localized at 19~13 .2  [I, 2). The ~4 isoform of apoE 
has been identified as a factor increasing the risk for 
early- and late-onset Alzheimer's disease (AD) { 3-71. 
The risk of AD associated with the APOE"2 and 
APOE"3 alleles of the APOE gene is less clear. Corder 
and associates {8] studied 1 15 unrelated late-onset AD 
(LOAD) patients and observed a significant decrease 
in LOAD risk for subjects of the APOE2E3 genotype 
compared with those of the APOE3E3 genotype, the 
effect being strongest in those with an onset of AD 
between 60 and 66 years. Chartier-Harlin and co- 
workers (61 showed in a population of 34 patients with 
sporadic early-onset AD (EOAD) and 36 patients with 
sporadic LOAD, a significant protective effect of the 
APOE"2 allele. Although a number of studies con- 
firmed the lowered APOE'Z allele frequency in AD 
patients versus controls [9, lo), the association was 
not found by others. One study reported a significant 
increase in the frequency of the APOE"2 allele in Ital- 
ian patients with sporadic AD as well as in familial 
EOAD 111). An increased APOE"2 frequency was also 
reported for AD patients of African-American descent, 
while a decreased APOEX2 frequency was found in 
Caucasian AD patients 112). 
We have studied the APOE genotype in relation to 
risk and survival in 175 patients with clinically diag- 
nosed EOAD and 532 age-matched controls. Earlier 
we reported a significant association between the 
APOE'4 allele and the risk of EOAD in the same 
population of EOAD patients C7). The emphasis of this 
analysis was on the role of the APOEX2 allele in the 
pathogenesis of EOAD. 
Materials and Methods 
Patient Selection 
Patients were derived from a population-based epidemiologic 
study of EOAD [13]. In four northern provinces of the 
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Netherlands and the area of metropolitan Rotterdam, the 
study aimed at a complete ascertainment of all EOAD pa- 
tients in whom the onset of A D  was at or before the age of 
65 years. Age at onset was defined as the age at which mem- 
ory loss or changes in behavior were first noted [13}. To 
obtain a full ascertainment of patients, we asked colleagues 
in all nursing homes, psychiatric institutions, social-geriatric 
services, neurologic departments, and computed tomography 
(CT) facilities in these areas to provide us with the names 
of all dementia patients in whom the onset was at or 
before the age of 65 years. All patients were diagnosed with 
A D  in the period of January 1980 to July 1987. For this 
study, the diagnosis of probable A D  was independently con- 
firmed by two neurologists using a standardized protocol ac- 
cording to the National Institute of Neurological and Com- 
municative Disorders and Stroke-Alzheimer's Disease and 
Related Disorders Association (NINCDS-ADRDA) criteria 
for AD 113, 141. Included in the study were incident, i.e., 
newly diagnosed EOAD patients as well as prevalent EOAD 
patients, who may have suffered from the disease for a vari- 
able length of time before inclusion in the study. Of the 
175 (88%)) patients for whom data on APOE genotype were 
available, 34 (20%) were included within 1 year after diagno- 
sis, 29 (17%) 2 years after diagnosis, 32 (18%) 3 years, 18 
(lo%,) 4 years, and 62 (35%) 5 years or more after diagnosis. 
Patients were followed over time and in 1990 their vital 
status was last ascertained. The mean follow-up period after 
diagnosis was 6 years (range, 2-12 yr; SD, 2 yr). Of  the 175 
patients, 60 (34%) patients had died. 
For each patient, a control subject was selected matched 
for gender, age (within 5 years), and place of residence 1131. 
These controls were drawn randomly from the population 
register of the municipality where the patient was living at 
the time of diagnosis. All controls were screened on cogni- 
tion and none of them showed symptoms of dementia [ 131. 
Blood for APOE typing was available for 159 (80%) con- 
trols. Our preliminary analyses did not show a significant 
association between the APOE"2 allele and the risk of 
EOAD {15]. However, APOE"2 is a rare allele and, there- 
fore, the lack of association may be explained by the lack of 
statistical power. To exclude this possibility, we increased the 
statistical power of our study by including an additional 373 
control subjects (164 men and 209 women; mean age, 63 
yr; SD, 4.2 yr). These subjects had been screened for demen- 
tia as part of another population-based study conducted in 
Rotterdam, the Rotterdam Study [161. None of them had a 
score lower than 26 on the Mini Mental State Examination 
1171 or showed symptoms of dementia at the time of the 
study. The allele frequencies of APOE"2 (9%), APOE"3 
(7495), and APOE*4 (17%) in the additional 373 controls 
did not differ significantly from those of the original 159 
controls C71. 
For all patients and controls, detailed data on family history 
of dementia in first degree relatives were collected 113, 161. 
To increase the validity of the family history obtained from 
a next of kin, the data were verified by a sibling of the patient 
[7, 131. The family history of subjects with no first-degree 
relatives with dementia was classified as negative and of those 
with at least one first-degree relative with dementia as posi- 
tive. In 19 families, AD appeared to be inherited as an 
autosomal dominant disorder. 
D N A  Analysis 
APOE typing for the 175 EOAD patients and 159 controls 
of the original case-control study has been described earlier 
171. For the additional 373 controls derived from the Rotter- 
dam Study [16], genomic D N A  was used for genotyping. 
The APOE gene was amplified using the primers and arnpli- 
fication conditions described by Wenham and colleagues 
[IS]. After amplification the polymerase chain reaction 
(PCR) product was digested with the restriction enzyme 
Hbal and fragments were separated by eleccrophoresis on a 
59% agarose gel. APOE alleles were visualized by ethidium 
bromide staining. 
EOAD has been shown to be genetically heterogeneous 
and may be caused by other genetic loci than APOE, i.e., 
mutations in the arnyloid precursor protein (APP) gene on 
chromosome 2 1 or a yet unidentified gene on chromosome 
14. These other loci may confound the association to APOE. 
However, by SSCP or PCR sequencing we found no muta- 
tions in exons 16 and 17 of the APP gene in a random 
sample of 100 patients 171. A linkage study of 10 informative 
families with autosomal dominant inheritance showed that in 
one family EOAD was conclusively linked to chromosome 
14 (q24.3). The proband of this family was excluded from 
the present analysis. In two families linkage to 14q24.3 could 
be excluded, while in none of the families AD could be 
conclusively linked to chromosome 19 or 21 1191. 
Statistical Analysis 
Allele frequencies for patients and controls were assessed by 
counting alleles and calculating sample proportions. The Z 
statistic was used to compare allele frequencies between 
groups [20]. Statistical testing was always performed at the 
conventional significance level (p) of 0.05. The strength of 
association between a genotype and the risk of EOAD was 
estimated as the odds ratio (OR) 1211, taking the most fre- 
quent genotype, APOE3E3, as reference. All ORs are ad- 
justed for age, gender, and place of residence by logistic 
regression analysis and are presented with 95% confidence 
intervals (95% CI) [21). In each regression model, all geno- 
types were included simultaneously. 
Kaplan-Meier analysis 1221 was used to estimate the sur- 
vival curves for the various APOE genotypes. Differences in 
survival curves were tested using Cox's proportional hazards 
model adjusting for age, gender, and place of residence 1231. 
Both methods take into account that not every patient was 
followed until death due to the termination of the follow-up 
of patients in 1990. In addition, we adjusted these analyses 
for the fact that not all patients were included in our study 
at rhe time of diagnosis [241. This phenomenon is referred 
to as left truncation and may result, if not corrected for, in 
an overestimation of duration of disease [24). 
Results 
The Table shows t h e  APOE genotype distribution for 
patients and controls, overall and stratified by family 
history of dementia or gender. There was no significant 
evidence for a protective effect on t h e  risk of EOAD 
for those with an APOE2E2,  APOE2E3, or APOE2E4 
genotype compared with those with the APOE3E3 
genotype. In men a statistically significantly increased 
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Genotype Frequencies of Apolipoprotein E Gene in Early-Onset Alzheimer's Disease Patients and Controls 
Overall Family History - Family History + Men Women 
Genotype Patients Controls (95% C1) Patients Controls (955% CI) Patients Controls (95% CI) Patients Controls (95% CI) Patients Controls (95% C1) 
ORa ORa OR" ORa OR" 
b 1 4 0.9 E2E2 3 6 2.2 3 6  3.8 0 0 - 2 2 5.4 
E2E3 22 88 1.4 10 67 1.1 12 21 1 4  12 37 2.5' 
(2%) (1%) (0.5-9.0) ( 4 % )  (1%) (0.9-15.7) (0%) (0%)  (3%) (1%) (0.8-35.0) (I%>) (1%) (0.1-8.0) 
0.7 10 51 
(13%) (17%) (0.8-2.5) (15%) (17%') (0.5-2.4) (11%) (15%) (0.6-3.1) (20%) (16%) (1.1-5.7) (9%) (17%) (0.3-1.5) 
E2E4 1 10 0.4 1 4 1.4 0 6 0 0 7 0 1 3 0.8 
(1%) (29%) (0.1-3.0) (2%) (1%) (0.2-12.0) (0%) (4%) (0.0-3.4) (095) (3%) (0.0-8.0) (1%) (1%) (0.1-7.4) 
(33%) (51%) Reference (41%) (53%) Reference (28%) (48%) Reference (31%) (48%) Reference (35%) (53%) Reference 
(35%) (27%) (1.3-3.1) (28%) (26%) (0.8-2.7) (40%) (30%) (1.3-4.3) (34%) (29%) (1.1-4.4) (36%) (26%) (1.3-3.5) 
(17%.) (2q,) (6.9-40.0) (10%) (2%) (2.8-26.4) (21%) ( 3 4 )  (4.2-36.5) (12%) (3%) (2.8-30.8) (19%) (2%) (6.4-44.8) 
28 207 1 30 66 1 18 110 1 40 163 1 E3E3 58 273 1 
E3E4 62 144 2.0' 19 102 1.4 43 42 2.4' 20 66 2.2' 42 78 2.1' 
E4E4 29 11 16.6' 7 7 8.6' 22 4 12.4' 7 6 9.2' 22 5 11.0' 
Total 175 532 68 393 107 139 59 228 116 304 
(100%) (100%) (100%) (100%) (loo%,) (100%) (100%) (100%;) (100%) (100%) 
aOdds ratio (OR) wrth 95% confidence interval (95% C1) 
bNo estimation of the odds ratio due to a division by 0. 
'Odds ratio statistically signlfrcantly ( p  < 0.05) increased. 
risk was found for those with the APOE2E3 geno- 
type. When pooling the APOE2E2, APOE2E3, and 
APOE2E4 genotypes, the risk associated with the 
APOE"2 allele was nonsignificant in the overall analysis 
(OR = 1.2 with 95% Cl  0.7-2.0) and in all subgroup 
analyses (family history -: OR = 1.4 with 95% CI 
0.7-2.7; family history +: OR = 1.0 with 95% CI 
0.4-2.2; men: OR = 1.9 with 95% CI 0.9-4.1 and 
women OR = 0.8 with 95% CI 0.4-1.7). 
There was no statistically significant difference in 
APOE"2 allele frequency between cases (8%) and con- 
trols (10%). Among patients, the APOE"2 allele fre- 
quency was related to the duration of illness at ascer- 
tainment. Figure 1 shows that within a period of 2 
years following diagnosis, the APOE"2 allele frequency 
was higher in EOAD patients compared with controls 
(14-15% vs lo%), while 3 years or more after diagno- 
sis the APOE"2 allele frequency was lower in EOAD 
patients (3-8%). This finding suggests that survival of 
EOAD patients carrying one or more APOE'2 alleles 
is reduced. In contrast, the APOE"4 allele frequency 
did not show a consistent decrease in time (see Fig 1). 
Independent of the duration of EOAD at ascertain- 
ment, the APOE"4 allele frequency in EOAD patients 
(25-45%) was always higher among EOAD patients 
than among controls (1 7%). 
To test whether patients' survival was influenced by 
the APOE genotype, we compared survival curves of 
EOAD patients with different APOE genotypes (Fig 
2). Mortality was highest in APOE"2 carriers and low- 
est in APOE"4 carriers. A significant 2.1 (95% CI 
1.1-4.3)-fold reduction in survival for APOE"2 carri- 
ers compared with APOE3E3 carriers was calculated. 
Although survival curves for APOE"4 and APOE3E3 
carriers crossed at 12 1 months after diagnosis, the sur- 
vival rate for APOE4E4 carriers remained significantly 
increased over time. For 56 (93%) of the 60 patients 
that died during the period of follow-up, information 
about the cause of death was available. Of the 16 de- 
ceased APOE"2 carriers, sepsis, pneumonia, infection 
diseases, cachexia, and dehydration were reported as 
the cause of death in 10 (63%). These are secondary 
complications that are commonly observed during the 
terminal stage of AD. Three (19%) patients died of 
cardiovascular disease and 2 (13%) of cancer. Cause 
of death was unknown in 1 (6%) patient. Of the 22 
deceased APOE"4 carriers, the cause of death was un- 
known for 2 (9%); 15 (68%) died of secondary compli- 
cations similar to those reported for the APOEX2 carri- 
ers, 4 (18%) of cardiovascular disease, and 1 (5%) of 
cancer. When comparing the death causes of APOE"2 
and APOE"4 carriers with those of the 22 deceased 
APOE3E3 carriers, no significant differences were ob- 
served. 
To adjust for possible biases due to the differential 
survival of patients related to their APOE genotype, 
we restricted the analysis to patients included in the 
study within 2 years after diagnosis. In this period, 
mortality among patients was low (see Fig 2) and, thus, 
no effect of differential survival is expected. Genotype 
frequencies of the selected 63  EOAD patients were 
APOE2E2 3%, APOE2E3 2196, APOE2E4 296, 
APOE3E3 17%, APOE3E4 3596, and APOE4E4 
22%. Compared with the frequencies of controls 
(see Table), the risk of EOAD was statistically sig- 
nificantly increased for the APOE2E2 (OR = 7.1; 
95% CI 1.3-37.8), APOE2E3 (OR = 3.6; 95% CI 
1.6-8.3), APOE3E4 (OR = 3.8; 955% Cl  1.8-8.1), 
and APOE4E4 (OR = 33.0; 95% Cl 12.4-88.4) 
genotypes. The risk associated with the APOE2E4 
genotype was nonsignificantly increased (OR = 2.3; 
959% CI 0.3-19.7). 
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Fig 1 .  Allele frequencies ofAPOE"2 and APOE'4 in earb- 
onset Alzheimer's disease (EOAD) patients by the number of 
years between diagnosis of EOAD and ascertainment o f  the pa- 
tient. The number of apolipoprotein E ulLeles and the total num- 
ber of alleles are given within the bars. Since each patient has 
two alleles, the total number of alleles equals double the number 
of patients. 
Discussion 
In our population, EOAD patients who carry APOE"2 
have a significantly reduced survival after diagnosis. 
When restricting the analysis to patients ascertained 
early after diagnosis at a stage of disease when mortality 
is low, our data suggest an increased risk of EOAD for 
subjects with APOE2E2, APOE2E3, APOE3E4, and 
APOE4E4 genotypes. Allelic association may result 
from (1) population admixture, which implies bias has 
occurred because the study population is a mixture of 
populations with different APOE allele as well as AD 
frequencies, (2) a direct role of APOE in the AD 
pathogenesis, or (3 )  linkage disequilibrium, which im- 
plies that the risk allele of an unknown causal gene 
always is accompanied by the APOE"2 or APOE"4 
allele, because APOE and the causal gene are close 
together on chromosome 19 and recombination during 
meiosis is unlikely. 
Although population admixture can never be fully 
excluded, it is unlikely that it occurred in our popula- 
tion as all patients and controls were derived from a 
homogeneous white population and were matched for 
residence. Evidence for the second explanation, a di- 
rect biological role of APOE in the AD pathogenesis 
is derived from studies suggesting a crucial role of 
APOE in PA4 amyloid deposition in senile plaques 
and angiopathy [25).  It has been suggested that this 
process is accelerated in APOE"4 carriers because 
apoE4 binds more readily to PA4 amyloid, making it 
less soluble [3, 261. Whether apoE2 also interferes 
with PA4 amyloid depositions remains to be proven. 
On the other hand, there is also some evidence for the 
third explanation, linkage disequilibrium, in which case 
APOE will be associated with the EOAD risk, although 
it is not implicated in the AD pathogenesis itself. It 
has been shown that the APOE gene is in linkage dis- 
equilibrium with neighboring genes 127) and an asso- 
ciation of APOE with EOAD and LOAD with poly- 
morphic markers flanking the APOE gene has been 
reported [b, 281. A typical feature of linkage disequi- 
librium is that in different populations, different alleles 
may be associated to the disease. APOE"4 has been 
consistently shown to be a risk factor for AD in the 
present and earlier studies 13-12]. However, the dif- 
ferential effect of APOE'2 on AD risk in different 
populations is compatible with linkage disequilibrium 
In addition to linkage disequilibrium, there are sev- 
eral other explanations for the discrepancy between 
studies of the role of APOE"2 in AD possible. In the 
subgroup of EOAD patients, genes other than APOE 
may confound studies. This explanation for the lack of 
a protective effect of APOE"2 for EOAD is less likely 
in our study. A protective effect of APOE"2 for 
EOAD has been shown by Chartier-Harlin and associ- 
ates C6); and in the study of Corder and colleagues 181 
the AD patients with an early onset age, i.e., between 
60 and 66 years, showed the strongest evidence for a 
protective effect. In contrast, we did not find evidence 
for a reduced risk of AD associated with the APOE2E3 
genotype when we analyzed only EOAD patients be- 
longing to this age category (OR = 1.7 with 95% CI 
0.7-4.6). Further, the APOE"4 [7}  nor the APOE"2 
allele frequency was associated with age-at-onset in our 
EOAD patients, suggesting a similar association of 
APOE"4 and APOE"2 to the risk of EOAD in all age 
categories up to 65 years. Another explanation may be 
that mutations may have occurred in the rare APOE"2 
allele that lead to an increased risk of AD. The new 
[6, 8-12). 
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F i g  2. Survival of early-onset Alzheimer's disease patients by 
upolipoprotein E (APOE) genotype. Included are 58 subjects of 
the APOE3E3 genotype, 91 APOE"4 carriers, and 25 APOE"2 
curriers. One subject of the APOE2E4 genotype has been ex- 
cluded. 
APOE alleles resulting from such mutations may be 
important determinants of AD risk in some popula- 
tions but not in others, e.g., because of genetic drift. 
Such a mechanism cannot be excluded unless the 
APOE gene is fully sequenced in all patients. Further- 
more, other genes or environmental factors may mod- 
ify the expression of APOE resulting in differ- 
ences between populations. In this light, our finding 
that the increased risk of EOAD for APOE"2 carri- 
ers was strongest in men is of interest, as men may have 
a different profile of environmental exposure than 
women, particularly with regard to cardiovascular 
factors. 
Our finding of a reduced survival of EOAD patients 
with an APOE"2 allele contributes another explanation 
to the controversial findings. Studies of prevalent pa- 
tients, which include patients who suffer from the dis- 
ease for an indefinite number of years, tend to exclude 
early fatalities and therefore are likely to overrepresent 
patients who survive longer [29). Bias may occur in 
particular when the risk factor studied is associated 
with survival 1291. When EOAD patients with one or 
two APOE"2 alleles have a reduced survival, APOE"2 
carriers may have been selectively removed from the 
patient population over time. This may result in an 
artificial decrease of the APOE"2 allele frequency and 
subsequently in an artificial decrease in risk associated 
with APOE"2 when'patients are compared with con- 
trols. The shift over time in the APOE"2 allele fre- 
quency in our EOAD patient population supports 
the view that reduced survival of APOE"2 carriers 
may bias risk estimation in a population of prevalent 
EOAD patients. In a similar way, the increased survival 
of APOE4E4 carriers may have led to an overrepresen- 
tation of APOE"4 carriers. Adjusting for the differen- 
tial survival by genotype by restricting the analysis to 
a period in which mortality was negligible, our study 
suggests that the APOE'2 and APOE"4 allele are both 
genetic risk factors for EOAD. 
The APOE"2 allele has been associated with longev- 
ity in a population of centenarians 1301. Our finding 
that patients carrying an APOE"2 allele have a reduced 
survival therefore suggests that the apoE2 protein, or 
perhaps a protein in disequilibrium, may accelerate the 
pathological process underlying EOAD. This finding is 
in line with the increased risk of EOAD that we found 
for APOE"2 carriers. An important issue to resolve, 
however, is the apparently contradictory finding that 
the APOE4E4 genotype is associated with an increased 
EOAD risk [G, 7) as well as with a prolonged survival 
of EOAD parients. Although our data and those of 
others suggest that clinically APOE genotypes may be 
used as predictors of AD risk and survival, many ques- 
tions on the role of APOE in the pathogenesis of AD 
are still unanswered. 
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